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Background:  Human  metapneumovirus  (HMPV)  has  been  shown  to cause  respiratory  infection,  account-
ing for  approximately  7% of  all such  disease,  and  contributes  to the  development  of  asthma  in  humans.
HMPV  has  a worldwide  distribution  with  infectivity  rates  approaching  100%,  and  immunocompromised
patients  are  particularly  at risk  from  viral  exposure.  No  anti-HMPV  vaccine  is  available  and  diagnosis  is pri-
marily based  on  in-house  molecular  or serological  tests,  in part due  to  limited  availability  of  recombinant
HMPV  antigens.
Objective:  To  generate  a  panel  of  HMPV-derived  recombinant  antigens,  develop  standardised  ELISA sys-
tems for  HMPV  IgG  detection  and  explore  the  nature  of B  cell  memory  against  HMPV  to  underpin  future
vaccine  studies.
Study design:  HMPV  viral  RNA  was  isolated  from  a  clinical  specimen  and  RT-PCR  was  conducted.  The
HMPV  M  and  P genes  were  cloned  and  expressed  in  Escherichia  coli. The  HMPV  N  gene  was  cloned  and
expressed  in  insect  cells  using  the  baculovirus  expression  system.  Each  purified  recombinant  antigens
was  subsequently  employed  in HMPV-specific  ELISA.
Results:  High-level  expression,  and  purification,  of  both  HMPV  matrix  (M)  (10  mg/g  cells)  and  phospho-
protein  (P)  (3.82  mg/g  cells)  were  achieved  in an  E.  coli  expression  system.  Recombinant  HMPV  (N)  was
successfully  expressed  in,  and  purified  from  the  baculovirus  expression  system.  Overall,  a  99%  HMPV  IgG
seroprevalence  was  observed  (n = 96)  using  HMPV  M-,  N-  and  P-ELISA,  respectively.  The  M  antigen  proved
to be  the  most  diagnostically  useful  with  99% of  specimens  tested  exhibiting  anti-M  protein  reactivity.  A
high  correlation  was  observed  between  anti-M  and  N IgG  reactivity  (r =  0.96),  with  significant  correlation
also  evident  for  anti-N  and  P  IgG reactivity  (r  =  0.74).  Lowest  correlation  was  evident  for  anti-M  and  P IgG
reactivity  (r  =  0.57).  Finally,  the  first  demonstration  of  HMPV-specific  B  cell  memory  (ranging  1–15  spot
forming  cells  (SFC)/million  cells)  was  achieved  against  M and  P antigens  in 40%  of individuals  tested.
Conclusion:  This  work  describes  robust  diagnostic  systems  for  HMPV  and  new  insight  into  antigen-specific
B  cell  memory  against  HMPV.. Background
Viral respiratory diseases are a major health problem. They
ffect people of all ages and exert a great economic impact on the
ealth care system. The viruses most often associated with res-
iratory tract illness include influenza virus, parainfluenza virus,
espiratory syncytial virus (RSV), adenovirus, rhinovirus and coro-
avirus. In 2001, Van den Hoogen and colleagues first reported the
iscovery of a new respiratory virus (human metapneumovirus,
MPV) in the Netherlands.1 Serological studies have revealed that
∗ Corresponding authors. Tel.: +353 1 7083858.
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virtually all children have been exposed to HMPV by the age of 5
years.1–5 Similar studies seem to support this hypothesis.6–10 How-
ever, in other case studies HMPV infections have been reported in
the elderly11–14 and immunocompromised individuals,15–19 which
suggests that the virus is not strictly limited to infecting infants
or children. Since its discovery, the occurrence of HMPV has been
reported in many countries, such as Australia, Canada, Finland,
United States, United Kingdom, Spain, Ireland, Israel and Japan. It
is now thought to be prevalent worldwide, indicating that it is a
common and ubiquitous human pathogen.20–22
The clinical manifestations of HMPV include tachypnea; rhi-
norrhea; nasal congestion; cough; fever; hypoxia; pharyngitis;
hyperinflation; peribronchial cuffing; wheezing; bronchiolitis;
pneumonia and respiratory failure.23–25 Earlier recognition of this
virus was  delayed because it had been difficult to detect in cell
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ulture due to its slow growth and mild cytopathic effect, and
herefore awaited the development of reverse transcriptase-PCR
RT-PCR).
Considerable effort has been directed towards the elucidation
f the nature of the T cell response to HMPV,26–30 yet the nature
f B cell memory directed against HMPV remains unclear. Mem-
ry B cells make a significant contribution to protective immunity
nd are characterised in terms of (i) a rapid proliferative response,
ccompanied by cellular differentiation upon antigen re-exposure,
o produce affinity-matured, antibody-secreting plasma cells, (ii) a
ower activation threshold relative to naïve B cells, in response to
ytokine and antigen presence and (iii) an absence of spontaneous
g secretion.31 Evaluating B cell memory may  have considerable
mportance with respect to the investigation of immunological
emory to HMPV and prove useful in the elucidation of virus-
pecific B cell mediated immunity to HMPV.
. Objectives
To generate a panel of HMPV-derived recombinant antigens,
evelop standardised ELISA systems for HMPV IgG detection and
xplore the nature of B cell memory against HMPV to underpin
accine studies.
. Study design
.1. Isolation of RNA from a clinical specimen and RT-PCR
Briefly, RNA was isolated from a bronchoalveolar-lavage (BAL)
rom a 48 year old female patient (ROI135). This HMPV isolate
as genotype A2. RT-PCR was conducted using a Qiagen one step
T-PCR kit. Three genes the HMPV Matrix (M)  0.8 kb; HMPV phos-
hoprotein (P) 0.9 kb and the HMPV nucleoprotein (N) 1.2 kb were
mplified.
.2. Cloning of HMPV M and P genes in Escherichia coli
The HMPV M and P gene sequences were ampli-
ed using oligonucleotide primers for the selected
egions (M-For: GAGAAGGCCTATG GAGTCCTACCTAGTA-
AC and M-Rev: GAGACTCGAGTCTGGACTTCAGCAC; P-For:
AGAAGGCCTATGTCGTTCCCTGAAGGA and P-Rev: GAGACTCGAG
ATAATTAACTGGTAGATGTC, restriction sites StuI and XhoI are
nderlined), ensuring that optimal directional cloning into the
ProEXTM HTb expression vector (Fig. 1). The HMPV M PCR cycling
onditions were 95 ◦C for 2 min  followed by 30 cycles of 94 ◦C for
 min, 65 ◦C for 1 min, 72 ◦C for 1 min, and a final extension step
f 72 ◦C for 10 min  in a Perkin-Elmer (Warrington, Cheshire, U.K.)
400 model thermal cycler. The HMPV P PCR cycling conditions
ere identical to that of the M gene with the exception of an
nnealing temp of 63.5 ◦C.
.3. Expression and purification of HMPV M
Expression of HMPV M protein was induced by the addition of
sopropyl -d-thiogalactoside (IPTG; 0.6 mM final) under the con-
rol of the lac promoter (Fig. 1). The M protein was highly insoluble
nd was present in the cell pellet as determined by SDS-PAGE
nd Western blot analysis using monoclonal antibody reactivity
gainst a His6 tag present on recombinant M protein and was
herefore purified from inclusion bodies using a differential pro-
ein extraction method. Briefly, 3 h post-induction, cells were lysed
y incubation with lysozyme (90 g/ml) and sodium deoxycholate
0.04% (w/v)), in the presence of protease inhibitor cocktail. Cell
ebris was removed by centrifugation at 10,000 × g for 10 min.ical Virology 52 (2011) 236– 243 237
Inclusion bodies were washed twice in 25 mM  Tris, 1 mM EDTA
(containing Triton X-100) pH 8.0, followed by a third 25 mM  Tris,
2 M urea pH 8.0 wash. Centrifugation was  performed as described
above. The final protein pellet was  solubilised by the addition
Tris (25 mM;  pH 8.0) containing 8 M urea, 1 mM EDTA and 2 mM
dithiothreitol (DTT) with agitation for 30 min at room temperature.
Aliquots of purified HMPV M protein were stored at −20 ◦C. Recom-
binant HMPV M (250 g/ml) was serially dialysed from the 8 M urea
buffer to 50 mM sodium carbonate, pH 9.4.
3.4. Expression and purification of HMPV P
Expression of HMPV P protein was  induced similar to that of the
M protein. The HMPV P protein was expressed with an N-terminal
His6-tag to aid protein purification (Fig. 1). The recombinant HMPV
P protein was purified by Ni-NTA chromatography (Qiagen, West
Sussex, U.K.) under denaturing conditions.
3.5. Cloning and expression of HMPV N in Spodoptera frugiperda
9 (Sf9) insect cells
It was necessary to design primers to amplify these regions
for molecular cloning into the pBlueBac 4.5 V5-His vec-
tor. Oligonucleotide primers were designed for the selected
region (N-For: ACAGGATCCGATGTCTCTTCAAGGGATTCAC, N-Rev:
TATGAATTCGCCTCATAATCATTTTGACTG, and the PCR product was
digested and ligated into the BamHI/EcoRI sites (restriction sites are
underlined) of the pBlueBac 4.5/V5-His vector (Fig. 1). The HMPV N
PCR cycling conditions were 95 ◦C for 2 min followed by 30 cycles
of 94 ◦C for 1 min, 54.2 ◦C for 1 min, 72 ◦C for 2 min  30 s, and a final
extension step of 72 ◦C for 10 min.
Recombinant HMPV N protein was  purified from whole cell sus-
pensions (2 × 108 cells), lysed in 16 ml  lysis buffer (20 mM  Tris–HCl,
8 M urea, 300 mM NaCl, pH 8.0), by His6-affinity chromatography
under denaturing conditions.
3.6. MALDI–ToF mass spectrometry (MS)
MALDI–ToF MS  was carried out using an Ettan MALDI–ToF mass
spectrometer (Amersham Biosciences (Europe) GmbH, Freiburg,
Germany). Protein samples were excised from the gel and pro-
cessed as described.32
3.7. Immunoblot and immunosorbent assay (ELISA) analysis
Immunoblots were conducted to assess IgG reactivity to the
denatured form of each HMPV antigen. Briefly, each recombinant
antigen was  solubilised in SDS sample buffer (0.15 M Tris–Cl, pH
6.8, 4.6% SDS, 23% glycerol, and 0.2 M DTT in 0.1% (w/v) bro-
mophenol blue) and heated at 100 ◦C for 5 min, prior to layering
onto a SDS-PAGE gel (12.5%). After SDS-PAGE, proteins were elec-
trophoretically transferred to nitrocellulose (NCP, Schleicher &
Schuell, 0.45 m pore size). Proteins were transferred at 120 mA
in a transblotting chamber (Bio-Rad Instruments), for 1 h at 4 ◦C,
using 25 mM Tris–HCl, 150 mM glycine, 20% (v/v) methanol. After
transfer, the blots were blocked by incubation with 5% (w/v) non-fat
milk powder in PBS for 1 h at room temperature. The membranes
were then cut into strips and incubated for 1 h with human serum
(1/100). Anti-His6 monoclonal antibody was  used as positive con-
trol for protein presence. The immuno-strips were washed 3 times
in PBS, containing 0.05% v/v Tween-20 (PBST) and then incubated
with horseradish peroxidase (HRP)-conjugated anti-human IgG
(Dako A/S, Glostrup, Denmark) for 1 h. Following a wash step (4
times with PBST), immuno-reactive strips were visualized using 3,
3′-diaminobenzidine (DAB).
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Fig. 1. (A) RT-PCR analysis of each of the HMPV genes. The PCR products for each gene were visualised on 1% (w/v) agarose gels. HMPV M cDNA product at 885 bp (lane 1);
HMPV  P cDNA product at 909 bp (lane 2); and HMPV N cDNA product at 1200 bp (Lane 3). DNA molecular weight Marker VII (Roche, lane M).  (B) Schematic of the HMPV
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Human sera were evaluated for HMPV IgG reactivity to the
ecombinant HMPV M,  P, and N proteins by ELISA. Assay procedures
ere identical to that of Corcoran et al.31 Immunoassay cut-offs
ere determined as the absorbance + 2 standard deviations greater
han the mean absorbance obtained from a panel of HMPV IgG neg-
tive samples (negative by ELISA and Western immunoblots to all
hree antigens) and an index value (I.V.) less than 1.0 was  consid-
red seronegative. Seroreactivity were grouped into the following
ategories: seronegative (I.V. ≤ 1); weak seropositive (I.V. of 1–2);
edium seropositive (I.V. of 2–4); high seropositive (I.V. ≥ 4).
.8. B cell memory ELISpot assay
Briefly, peripheral blood mononuclear cells (PBMC) were iso-
ated, quantified and cultured for five days in complete RPMI in the
resence of heat-killed Staphylococcus aureus cells ((SAC); Cowan strain) and interleukin-2 (IL-2). SAC and IL-2 jointly function
o induce generalised antibody production in resting memory B
ells. HMPV antigen-specific memory B cells were washed and
uantified, as spot forming cells (SFC), by ELISpot technique asroEX Htb constructs for recombinant protein expression in E. coli. A stop codon was
ox). The HMPV/pBlueBac 4.5/V5-His construct for recombinant protein expression
te translation (shaded box).
previously described,31 except that HMPV antigens were used for
B cell capture.
4. Results
4.1. Expression of HMPV M
The expression of foreign proteins at high levels in E. coli often
results in the formation of inclusion bodies of insoluble aggre-
gates of the expressed protein. The HMPV M recombinant protein
(32 kDa) was highly insoluble (present in the cell pellets), and was
purified from inclusion bodies under denaturing conditions using
differential extraction. The inclusion bodies were recovered from
bacterial cell lysates by centrifugation and washing with Triton X-
100 and EDTA to remove as much bacterial protein as possible from
the aggregated protein. To obtain soluble HMPV M protein, the
washed inclusion bodies were dissolved in denaturing agents and
the released protein was  refolded by gradual removal of the dena-
turing reagents by dilution and dialysis. A 32 kDa HMPV M band
was  observed following SDS-PAGE (Fig. 2), this was consistent with
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Fig. 2. SDS-PAGE analysis of each recombinant HMPV antigen. (A) HMPV M recombinant protein. Clarified cell lysate (lane 1), purified HMPV M at 32 kDa (lane 2). (B) HMPV P
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ecombinant protein. Clarified cell lysate (lane 1), purified HMPV P at 29 kDa (lane 2
 (lane 1), Ni-NTA affinity-purified HMPV N (47 kDa) (lane 2). Molecular Mass Ma
riefly, samples were electrophoresed on 12% SDS-PAGE gels at 120 V under reduci
he predicted Mr  of the M protein including the His6 tag region at
1.6 kDa (Table 1). The purification process yielded 10 mg  M pro-
ein/gram of cells. MALDI–ToF MS  analysis of recombinant HMPV following trypsin digestion confirmed the identity of recombi-
ant HMPV M (GenBank accession no. gi|24429832) whereby 6/15
eptides (36% sequence coverage) was observed (Table 2).
able 1
he predicted, versus actual Mr  by SDS-PAGE, of each recombinant HMPV pro-
ein. The computation of the theoretical pI (isoelectric point) and Mr  was
etermined using http://expasy.org/tools/pi tool.html from the Swiss Institute of
ioinformatics.
Protein ID Predicted
pI
Predicted
Mr (kDa)
Predicted
Mr + His tag
(kDa)
SDS-PAGE
Mr (kDa)
M 8.2 27.6 31.6 32
P  4.81 32.71 36.7 29
N 6.73 43.51 47.5 47
able 2
ass spectrometry analysis of purified HMPV recombinant antigens. Sequence cov-
rage of 35–56% confirmed the identity of each HMPV recombinant antigen.
Protein Peptides identified % Sequence
coverage
Protein ID
HMPV M K. TLTITTLYAASQSGPILK.V
K.VNASAQGAAMSVLPK.K
K.FEVNATVALDEYSK.L
K.NTPVTIPAFIK.S
K.ESESATVEAAISSEADQALTQAK.I
K.TWSHQGTRYVLK.S
(6/15) 36% gi|24429832
HMPV P K. DILFMGNEAAK
K.LAEAFQK
K.VNTVSETLELPTISRPTKPTILSEPK
K.KLAWTDK
K.LKPSTNTKK
K.LKPSTNTKKK
K.KVSFTPNEPGK
K.DALDLLSDNEEEDAESSILTFEER
R.DTSSLSIEARLESIEEK
R.LESIEEK
K.LSMILGLLR
(12/28) 56% gi|45388092
HMPV N K.YAAEIGIQYISTALGSER
R.VQQILR
K.GEDLQMLDIHGVEK
K.LASTIEVGLETTVR
R.VLSDALKR
R.SFYDLFEQK
R.SLFIEYGK
K.AESLFVNIFMQAYGAGQTMLR
K.AESLFVNIFMQAYGAGQTMLR
R.WGVIAR
R.GRVPNTELFSAAESYAK
R.VPNTELFSAAESYAK
(12/25) 35% gi|38327234MPV N recombinant protein. Clarified supernatant from Sf9 cells expressing HMPV
ew England; P7703 (lane M)). SDS-PAGE was conducted according to Laemmli.35
dition for 1.5 h. Gels were stained with Coomassie Brilliant Blue R-250 (Sigma).
4.2. Expression of HMPV P
Recombinant P protein was observed at 29 kDa following SDS-
PAGE analysis (Fig. 2). The predicted Mr  of the P protein plus the
His6 tag region is 36.7 kDa (Table 1). The discrepancy between the
observed and predicted Mr  may  be attributed to the fact that the P
protein has a low isoelectric point (pH 4.8) and therefore migrates
further upon SDS-PAGE. The P Protein was  purified by His6 affinity
chromatography under denaturing conditions. The relative yield of
purified P protein was  3.82 mg/g of lysed E. coli (Fig. 2). MALDI–ToF
MS analysis of recombinant HMPV P following trypsin digestion
confirmed the identity of recombinant HMPV P (GenBank accession
no. gi|4588092) with 56% sequence coverage (Table 2).
4.3. Expression of HMPV N in Sf9 insect cells
Insect cells were infected with recombinant baculovirus-
encoding HMPV N at multiplicity of infection (MOI) = 10. The HMPV
N recombinant protein was successfully purified by His6 affinity
chromatography under denaturing conditions using an AKTA chro-
matography system (Amersham). Purification resulted in a single
major protein band a molecular mass of 47 kDa (Fig. 2). The puri-
fied protein yield was  1.5 mg/1 × 108 cells. MALDI–ToF MS  analysis
of the purified HMPV N protein confirmed identity with a 35%
sequence coverage (Table 2).
4.4. Immunological analysis
To define the seroepidemiology of HMPV in an Irish popu-
lation, ELISA systems were developed using three recombinant
HMPV proteins as detection antigens. To investigate the seropreva-
lence of HMPV, a total of 96 human sera were screened by ELISA.
Sera from this blood donor cohort (n = 96) were analysed in dupli-
cate by ELISA against E. coli-expressed HMPV M and P antigens
and the baculovirus-expressed HMPV N protein. To establish the
immunoassay cut-offs for each of the HMPV ELISAs, a panel IgG
negative sera from healthy individuals were identified by ELISA
and Western immunoblots (Fig. 3). The cut-off was established
as the absorbance + 2 standard deviations greater than the mean
absorbance obtained from a panel of HMPV IgG negative samples
(negative by ELISA and Western immunoblots to all three antigens)
and an I.V. less than 1 was considered seronegative.
Of the total number of seropositive serum specimens (99%);
58% were weakly seropositive, 30% were showed medium serore-
activity and only 11% had high human IgG reactivity to the
E. coli-expressed M antigen (Table 3). This extensive seroreactiv-
ity suggests that the M antigen binds IgG with high affinity or that
the occurrence of specific anti-HMPV M IgG is common.
For the recombinant P ELISA, the overall total percentage
seropositivity was 74% (70/96) and 26% were seronegative (Table 3).
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Fig. 3. Human sera (n = 20) screened using IgG immunoblot containing denatured HMPV antigens. (A) HMPV M protein, (B) HMPV P protein and C. HMPV N protein. A
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ositive  control (C) was  used (i.e., an immunostrip probed (1/1000)) with anti-His6
epresentative set of 20 serum samples from the 96 sera tested by ELISA is shown. Pr
rilliant Blue R250, this was  to ensure that 1 g of each antigen was  loaded per stri
his suggests that the IgG in human sera is immunoreactive
gainst the recombinant P protein. In fact, of all seropositive
pecimens (74%), 27% were weakly seropositive, 28% exhibited
edium seroreactivity and only 19% had high IgG reactivity to the
able 3
he percentage human IgG antibody reactivity to HMPV-M, P and N recombi-
ant antigens. Seroreactivity is grouped into the following categories: seronegative
I.V. ≤ 1); weak seropositive (I.V. of 1–2); medium seropositive (I.V. of 2–4); high
eropositive (I.V. ≥ 4). Each category was scored as a percentage of the total number
f  sera screened.
Protein 
ID
Seronegative Weak 
Seropositive 
Medium 
 Seropositive 
High 
 Seropositive
99% (95/96) Total Seropositive
M 1%  (1/96) 58%  (55/96) 30% (29/96) 11%  (11/96)
74% (71/96) Total Seropositive
P 26%  (25/96) 27%  (26/96) 28%  (27/96) 19%  (18/96)
91% (88/96) Total Seropositive 
N 9%  (8/96) 58%  (56/96) 32%  (31/96) 1%  (1/96)clonal antibody which reacts with the His6 region on each recombinant antigen. A
electrotransfer, a 1 mm strip was removed from the gel and stained with Coomassie
 (+) and (−) signs indicate IgG positive and IgG negative specimens, respectively.
antigen. Therefore there was  lower seroreactivity observed via
ELISA within the sera cohort and may  suggest that the P antigen
is not as diagnostically useful as HMPV M.
For the recombinant N ELISA, the overall total percentage
seropositivity was 91% (87/96), and 9% of specimens exhibited no
reactivity against recombinant N antigen (Fig. 3). This data demon-
strate that using the M protein results in a higher sensitivity than
using the N protein, when subjected to ELISA analysis. Of the 96
specimens screened, 58% were weakly seropositive, 32% showed
medium seroreactivity and only 1% had high IgG reactivity to the
recombinant HMPV N antigen.
Table 4 shows the sequence identity between HMPV M,  P and N
proteins used in this study, compared to exemplar isolates repre-
sentative of genotypes A1, B1 and B2.
4.5. Immunological memory analysis by B cell ELISpotThe use of an HMPV-specific B cell ELISpot offered the possibility
to confirm past exposure to, and infection with, HMPV. It can be
seen from Fig. 4 that all individuals (n = 10) screened were HMPV
IgG seropositive with the exception of one individual (E10) who
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Fig. 4. ELISA and B cell ELISpot assay. (A) ELISA of human IgG response in plasma obtained from adult volunteers (n = 10) against the HMPV viral proteins M and P, expressed
as  index values (I.V.). An index value above 1 is considered seropositive. Serum E10 is from a seronegative individual (negative control). (B) B cell memory, directed against
HMPV  antigens, are expressed as SFCs/1 million starting cells and are the mean ± SD of the triplicate wells. ELISpot microplates were coated with either HMPV M protein
(grey) or HMPV P protein (dark shaded) at 10 g/ml, respectively. C. Reactive memory B cells to both HMPV M and HMPV P recombinant antigens. Buffer only (negative
control  (NC), no antigen was  coated on the plate) and positive control (PC) (anti-human IgG on the plate to detect all activated memory B cell which secreted IgG). (Scale = 10×
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as seronegative by ELISA. The seronegative individual (E10) and
our seropositive individuals (E4, E5, E6 and E7) did not appear to
arbour high levels of HMPV-specific memory B cells (Fig. 4). Five
eropositive individuals (E1, E2, E3, E8 and E9) exhibited detectable
able 4
he percentage protein sequence identity for each HMPV antigen from isolate
OI135 genotype A2 compared to representative isolates from each of the other
MPV genotypes. The GenBank accession number of each isolate is as follows: JSP03
AY530092); NL-1-99 (AY525843) and BJ1816 (DQ843658).
HMPV isolate Genotype % Sequence identity
M protein P protein N protein
JSP03 A1 98.8 96.3 99.5
NL-1-99 B1 97.2 85 95.2
BJ1816 B2 97.2 86.1 96.2(range: 1–14.6 SFC/million B cells) HMPV-specific B cell memory
against HMPV M and HMPV P antigens (Fig. 4).
5. Discussion
To define the seroepidemiology of HMPV in an Irish popula-
tion, we  developed enzyme-linked immunosorbent assays (ELISAs)
based on the expression of HMPV M and P proteins in E. coli
and the recombinant HMPV N produced in Sf9 insect cells.
A sero-epidemiological survey using these HMPV recombinant
antigen-based ELISA systems was employed to determine the
prevalence of antibodies to specific HMPV proteins in Ireland. The
total antibody reactivity to HMPV M,  P and N antigens correlated
well, in particular there was  significant correlation between the
seroreactivity observed in both the M and N ELISA systems, (r = 0.96;
Table 3). The correlation between the presence of HMPV antibodies
determined by the M and P ELISAs was lower (r = 0.57) compared
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o the correlation between HMPV M and N ELISAs. Significant cor-
elation was also observed between the N and P ELISAs (r = 0.74).
he lack of correlation between the M and P protein-based ELISA
ystems may  be due to variable levels of IgG to each recombinant
ntigen within the selected donor cohort. Ishiguro et al. tested
or specific antibodies against nucleocapsid (N) and matrix (M)
roteins in 97 sera by Western blot using recombinant N and M
roteins of HMPV expressed in E. coli.33 The results were com-
ared with those of immunofluorescence assays (IFAs) based on
MPV-infected LLC-MK2 cells, which expressed the whole HMPV
roteome. Their results indicated that the antibodies against N and
 proteins are highly specific (100%) but less sensitive (42.1%, N
rotein; 40.8%, M protein) than those against whole proteins of
MPV detected by IFA. This would also suggest that a multi-HMPV
ntigen ELISA would increase the sensitivity of the detection of
MPV antibodies within human sera. However, the lower detection
f P antigen-specific IgG may  be due to the relatively low percent-
ge sequence identity between HPMV P (from the A2 genotype) and
enotypes A1 B1/2, respectively.34 The HMPV genotype A2 proteins
M,  P and N from ROI135) used in this study exhibited 97.2–98.8,
5–96.3, and 95.2–99.5% sequence identify to selected examples
f genotypes A1 and B1/2, respectively (Table 4). Extensive valida-
ion of the HMPV ELISA systems described herein, whereby antigen
oating on microtitre plates was optimised (2, 3 and 5 g/ml for
MPV M,  P and N, respectively) and assay reproducibility, in terms
f % coefficient of variation, was determined to be 5.5, 8 and 8%,
espectively, preclude sub-optimal assay performance as a reason
or the observed differences in antibody detection. In summary,
ecombinant M,  P and N proteins of HMPV were antigenic, and
he responses to M,  P, and N proteins differed across the study
opulation. Assays based on multiple antigens provided higher sen-
itivities than assays based on single antigens.
The defining feature of the acquired immune system is its abil-
ty to generate immunological memory to a particular pathogen
n defence of re-infection. Recently, considerable efforts have been
irected towards the elucidation of the nature of the T cell response
o HMPV and the definition of T cell epitopes,26–30 yet the nature
f B cells memory directed against HMPV remains unclear. All indi-
iduals (n = 10) screened were HMPV IgG seropositive with the
xception of one individual E10, who was seronegative for HMPV
pecific IgG (Fig. 4). Five individuals (E1, E2, E3, E8 and E9) exhib-
ted low, but detectable (range: 1–14.6 SFC/million B cells) B cell
emory. There was a significant correlation between the number
f memory B cells directed against HMPV M and HMPV P antigens
r = 0.655). However, the greatest numbers of SFCs were evident in
wo individuals (E1, mean ± SD: 13.5 ± 1.2 SFC/million cells and E9,
4.7 ± 2.2 SFC/million cells). B cell memory could not be detected
n the absence of IL-2 and SAC stimulation prior to ELISpot analysis,
hich was an unstimulated B cell control (Fig. 4).
When the IgG reactivity of the ten specimens (E1–E10) against
MPV M was analysed by ELISA and compared against the B
ell ELISpot data, no statistically significant positive correlation
as observed between SFC/million cells and antibody reactivity
r = 0.022). Conversely, a correlation was observed between the
LISpot results and IgG reactivity to the HMPV P antigen (r = 0.655)
or individuals exhibiting IgG specific antibody responses to the
MPV P antigen. This confirms that previous exposure to HMPV
lso results in B cell memory (mainly individuals E1 and E9).
The lack of correlation between the ELISpot data obtained for the
 protein and that obtained for ELISA data is not unusual; the detec-
ion of specific serum antibodies is the most widely applied method
o investigate immunity against diseases like HMPV, although a
pecific correlate of protection against HMPV has not been estab-
ished yet. Besides antibodies, long-term memory B and T cell
mmunity might play an important role in protection against HMPV.
n some individuals, high antibody levels with low or no numbersical Virology 52 (2011) 236– 243
of memory B cells were found. This strengthens the idea that long-
lived plasma cells maintain antibody levels and that memory B cells
are a distinct population of cells. Memory B cells do not secrete
antibodies prior to activation. Upon renewed antigen stimulation,
memory B cells may  rapidly respond, proliferate and differentiate
in antibody secreting cells. The ongoing circulation of HMPV among
the Irish population causing antigenic re-challenge might explain
the low correlation between circulating HMPV-specific memory B
cells and antibody levels measured in our study. Importantly, in
some individuals no HMPV-specific memory B cells, as well as low
HMPV-specific antibody levels, were detectable which might result
in a higher susceptibility for infection with HMPV.
In conclusion, this work has provided multiple new detection
systems for, and establishes the seroprevalence of, HMPV IgG in an
Irish population. We  also report the first demonstration of HMPV-
specific B cell memory against HMPV M and P antigens which
furthers our knowledge on the antigen-specific B cell memory
against the HMPV viral proteins. Determination of antigen-specific
B cell memory status may  enhance the serological and molecular
analyses of persistent HMPV infection. Further studies are war-
ranted to elucidate the nature of differential seroreactivity to each
viral antigen.
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